Recently Featured

Jubilant HollisterStier Receives FDA Warning Letter for Quality Control Deficiencies

July 8, 2026
Jubilant HollisterStier, a contract development and manufacturing organization (CDMO) under Jubilant Pharmova, has been issued a warning letter by the FDA due to significant deficiencies in quality control systems at its Montreal production facility. This action follows an inspection that revealed critical lapses in compliance with established regulatory standards, raising concerns about the integrity of…

New Drug Candidate Targets LDL Receptor Pathway to Control Cholesterol

July 8, 2026
Researchers at the University of California, San Diego, have identified a novel biological pathway that could revolutionize cholesterol management. This discovery centers on a protein called Ral, which plays a critical role in the liver’s ability to clear low-density lipoprotein (LDL) cholesterol from the bloodstream. Despite the availability of various cholesterol-lowering medications, many patients struggle…

First-in-Human Stem Cell Therapy Trial for Huntington’s Disease Begins at UCI Health

July 8, 2026
The world’s first in-human embryonic stem cell-derived clinical trial for Huntington’s disease has launched at UCI Health, the clinical arm of the University of California, Irvine. The Phase Ib/IIa trial will evaluate the safety of hNSC-01 neural stem cells derived from embryonic stem cells delivered to the brain by a specialized neurological mapping and targeting…

Eli Lilly Invests $40 Million in AI Startup Absci to Develop Hair Loss Treatments

July 7, 2026
Eli Lilly has made a significant investment in the biotech startup Absci, contributing $40 million to a $100 million funding round aimed at developing innovative treatments for hair loss and potentially endometriosis. This move marks a strategic expansion for Lilly, known for its successful weight loss medications, into the aesthetic and dermatological markets. The investment…

Ongoing Cases